Objective: To investigate the rate of seropositivity of anti-JC virus (JCV) antibodies in a German multiple sclerosis (MS) cohort treated with natalizumab in the postmarketing setting and to assess anti-JCV serostatus in samples obtained before diagnosis of progressive multifocal leukoencephalopathy (PML).
Recently, the association of the ␣4-integrin antagonist natalizumab approved for the treatment of highly active relapsing multiple sclerosis (MS) with progressive multifocal leukoencephalopathy (PML) has revived interest in this rare, but potentially fatal, disease. 1-3 PML is caused by the JC (John Cunningham) virus (JCV), a common, opportunistic polyomavirus. Infection with JCV is considered to be one necessary but not the only prerequisite for the development of PML. Whereas studies to ascertain the utility of measuring JCV DNA have yielded conflicting results, recently a 2-step confirmatory ELISA for the serologic detection of anti-JCV antibodies has been proposed to assist in PML risk stratification. 4 -7 A previous study reported in a retrospective analysis of serum/plasma from 831 patients participating in natalizumab clinical trials that 53.6% were seropositive for anti-JCV immunoglobulin (IgG) with a trend to higher prevalence of anti-JCV antibodies in male patients and with increasing age. 6 Of 193 officially reported cases of PML as of December 2011, 112 occurred in Europe (Biogen Idec, data on file). In comparison with other European MS populations, MS prevalence in Germany is estimated to be very high (ϳ150 per 10 5 ); in addition, Germany has a relatively high proportion of patients treated with nonspecific immunosuppressant agents, presumably an epidemiologic risk factor for the development of PML. 8, 9 To better understand whether epidemiologic factors, including geography, gender, age, immunosuppressive pretreatment, and duration of natalizumab treatment influence the seroprevalence and levels of anti-JCV antibodies and the utility of serostatus for PML risk stratification, a large cohort of German patients with MS treated with natalizumab was investigated for anti-JCV antibodies. In addition, samples available from 10 natalizumab-treated patients collected before or at PML diagnosis were analyzed in a blinded fashion.
METHODS Standard protocol approvals, registrations, and patient consents. The retrospective observational study was approved by the responsible ethics committee (Ruhr University Bochum), who waived the requirement for informed consent because of the retrospective nature of the study, according to the Declaration of Helsinki, paragraph 25. Serum or plasma samples were obtained countrywide for routine testing for anti-natalizumab antibodies during open-label treatment between 2007 and 2010. 10 Sample size, storage, and analysis. All patients had at least one infusion of natalizumab during open-label treatment. All samples were stored frozen at Ϫ20 to Ϫ80°C until analysis. Anti-JCV antibody testing was performed blinded. Details of the two-step confirmatory assay have been published before. 6 In short, a detection ELISA was followed by a supplemental confirmation test with preabsorption of specific antibodies with soluble JCV-like particles. Anti-natalizumab antibodies were analyzed as reported before. 10 If more than one sample was available for an individual patient, the earliest was used for calculation of seroprevalence. The quantification of antibody reactivity/ level is reported as normalized optical density (nOD 450 ), as described by Gorelik et al. 6 Continuous variables are expressed as mean and SD or median and 25th and 75th percentile and categorical variables as percentages. For dichotomous variables, associations were tested with the Fisher exact 2-sided test or the 2 test, respectively, or the McNemar test for paired data. Relative risks (RRs) and exact 2-sided confidence intervals were used to estimate effect sizes. For continuous variables, the exact 2-sided U test (independent data) or the Wilcoxon signed rank test (paired data) was performed. Hodges-Lehmann point estimates and exact 95% Hodges-Lehmann confidence intervals (CIs) were estimated. Furthermore, a Spearman correlation coefficient was computed for 2 continuous variables. Subjects with missing data were omitted from the corresponding analyses. All results were considered significant with p Ͻ 0.05. All statistical analyses were performed using SAS version 9.2.
RESULTS
A total of 2,782 samples from 2,253 patients with MS were analyzed. Epidemiologic data for the patients are given in table 1. Complete datasets were available for 1,582 patients; only 4 patients had no epidemiologic data transferred. The rate of seropositivity in the total cohort was 58.8% (95% CI 56.8 -60.8). Overall, seroprevalence was higher in men (63.8%) than in women (56.7%, p ϭ 0.0024; RR 1.13; 95% CI 1.05-1.21) ( figure 1A ). Anti-JCV antibodies were detected more frequently with increasing age, with 48.9% of anti-JCV antibodypositive patients being Ͻ20 years of age and 72.5% of patients being Ն50 years ( p ϭ 2.81 ϫ 10 Ϫ5 ) (figure 1B). Also, in patients Ն50 years, men were more likely to exhibit anti-JCV antibodies than women (84.1% [95% CI 73.2-91.8] vs 66.4% [57.8 -74.3]; RR ϭ 1.27; 95% CI 1.08 -1.48). Between the age intervals 20 -29 years and 30 -39 years, a plateau in the rate of seropositivity was observed ( figure 1B ). Longitudinal stability of serologic status was assessed in 470 patients over 8 -9 months. Although serologic status remained stable for approximately 93% of patients, 19 of 194 patients (9.8%) who tested negative for anti-JCV antibodies at the first analysis subsequently converted to seropositive status during an average observation time of 7.7 months (SD 4.3). From 276 patients in whom anti-JCV antibodies were detected at the first available analysis, 13 patients (4.7%) subsequently became seronegative dur- ing an average observation time of 7.9 months (SD 4.1). We next addressed whether these conversions are related to natural fluctuations of antibody levels in patients with low antibody reactivity near the cut points of the assay. Samples obtained from the patients who reverted from seropositive to antibodynegative status showed antibody levels near the lower cut point of the ELISA (nOD 450 0.1) 6 in that antibody reactivity at the first measurement (median nOD 450 0.140, [25th-75th percentile 0.111-0.158]) was only slightly higher than that at the subsequent time point (nOD 450 0.094 [0.085-0.103], p ϭ 0. 0088). In patients who converted from seronegative to antibody-positive status, there was a larger difference in antibody reactivity between the first and the subsequent analysis (median nOD 450 at first time point 0.089 [0.070 -0.120]; nOD 450 at the subsequent time point 0.260 [0.118 -0.352], p ϭ 0.0005). In most patients who converted from seronegative to antibody-positive status (n ϭ 19), the levels were near the cut point. However, in 3 of these patients (15.8% of the seroconverters and 1.5% overall [3 of 194] ), there was a more pronounced increase in antibody levels (nOD 450 Ͼ0.4), suggesting a shift in the humoral response to the virus. For 49 patients in our cohort, more than 2 samples were available (mean 3.3, range 3-5) over an interval of 1.4 -26.5 months (mean 11.5). In all but 3 of these patients the serostatus obtained at the first time point remained stable over the subsequent testings. The 3 exceptions all had antibody levels that fluctuated be-tween positive and negative around the lower cut point of the assay. Patient 1 tested seropositive at the first time point (nOD 450 0.123), seronegative after 7.7 months (nOD 450 0.096), and again seropositive (nOD 450 0.149) after 8.5 months. A second patient tested seropositive 2 times (first time point nOD 450 0.117; after 0.9 months nOD 450 0.137) before his serostatus was assessed as negative twice (after 8.7 months nOD 450 0.079; after 13.6 months nOD 450 0.067). The third patient tested seronegative twice (nOD 450 0.071 at the first time point; nOD 450 0.066 after 3.8 months) before the last analysis after 16.9 months revealed seropositivity based on the confirmatory assay (nOD 450 0.176). There was no difference in the number of natalizumab infusions between anti-JCV antibodypositive patients (mean 8.7, SD 5.8) and antibodynegative patients (mean 8.6, SD 5.6); likewise, no difference in treatment duration was observed (mean 9.0, SD 6.5 months and mean 8.9, SD 6.7 months, respectively). In addition, with regard to anti-JCV antibody levels, there was no relationship to either number of natalizumab infusions (Spearman correlation coefficient r ϭ Ϫ0.01516, p ϭ 0.4894) or treatment duration (Spearman correlation coefficient r ϭ 0.00239, p ϭ 0.9147). Anti-natalizumab antibodies were detected in 3.0% of the patients. Occurrence of anti-natalizumab antibodies was not associated with anti-JCV antibodies (table 2) . Neither immunomodulatory nor immunosuppressive pretreatment altered the rate of seropositivity for anti-JCV antibodies (table 2). Specific subgroups (e.g., mitoxantrone pretreatment) did not exhibit different rates of anti-JCV antibody seropositivity (table 2 ). In addition, in the seropositive patients, levels of anti-JC virus antibodies did not differ between patients with immunosuppressive pretreatment (median nOD 450 0.864 [25th-75th percentile 0.471-1.277], p ϭ 0.1026), immunomodulatory pretreatment (0.579 [0.290 -0.974], p ϭ 0.8782) in comparison to patients without pretreatment (0.542 [0.207-1.080]).
In 10 patients from our cohort, PML was subsequently diagnosed (table 3) . For 9 patients, samples were available 2.0 -37.6 months before PML diagnosis; for 4 of these patients longitudinal samples could be obtained. Anti-JCV antibodies were detected in all patients with samples available before PML diagnosis (9 of 9 [100%], 95% CI 66 -100, significant difference compared with the overall cohort [58.8%], p ϭ 0.012, one-sample exact binomial test). In the 4 patients for whom longitudinal pre-PML samples were available, anti-JCV antibody seropositivity was persistent over an interval of 3.6 -26.3 months (table 3 ). In addition, the samples obtained at PML diagnosis were used, the percentage of patients with high antibody levels was higher in the group who developed PML than in seropositive patients who did not develop PML ( figure 2B ).
DISCUSSION Several epidemiologic risk factors for the development of PML in natalizumabtreated patients with MS have been proposed, e.g., immunosuppressive pretreatment and duration of natalizumab therapy. 9 However, thus far a validated biologic marker for quantifying the risk to develop PML, which has been prospectively corroborated in specific, large, and independent cohorts is lacking.
Here, we independently confirm and extend previous data pertaining to anti-JCV IgG antibodies de- tected with a 2-step ELISA in a cohort of Ͼ2,200
German-based patients with MS who were treated with natalizumab in the postmarketing setting. Although the rate of seropositivity reported here is in the range of that of other cohorts, our data are also consistent with other studies in European patients in that they appear to be more likely to be anti-JCV antibody-positive than patients from the United States. 6, 9 In our cohort, there was a higher antibody seroprevalence in male patients with a relative risk increase of 1.13. This observation also held true for patients Ն50 years of age who generally had a higher rate of seropositivity. There appeared to be a plateau in the rate of seropositivity between age intervals 20 -29 years and 30 -39 years, in which most of the patients investigated were clustered, in accord with high disease activity in these age groups. However, the overall increase in seroprevalence with increasing age argues for the need of frequent longitudinal testing in natalizumab-treated patients with MS. A potentially interesting group of patients to study in more detail are those whose anti-JCV antibody status changed. For the 4.7% of patients who became seronegative, our data suggest that this may be a natural fluctuation of antibody levels near the lower cut point of the assay (nOD 450 0.1). 6 Together with the typical, albeit low, analytical variability of the assay, 11 this may result in alternating positive and negative results. Similarly, most of the patients who converted from seronegative to seropositive status over the relatively short interval of this study also had antibody levels that appeared to fluctuate around the upper cut point of the assay (nOD 450 0.25). Values above the upper cut point are considered anti-JCV antibodypositive, whereas samples with nOD 450 values between 0.1 and 0.25 undergo a confirmation test with a competition step using soluble JCV-like particles. 6 Thus, in the majority of these patients the change in anti-JCV antibody status may not reflect a change in the humoral immune response to the virus but rather, e.g., naturally occurring fluctuations in antibody levels. This interpretation is consistent with our cross-sectional analyses of anti-JC virus antibody prevalence in relationship to age, which would argue for a lower annual seroconversion rate. However, 3 of the 194 patients (1.5%) who initially tested seronegative had a substantial increase in antibody levels (nOD 450 Ͼ0.4) at the second time point. This increase might indicate a change in the viral status for these patients as reflected in their humoral immune response to JCV. Such changes could include a new infection, a change in the viral load or a change in the site of viral infection. Additional prospective longitudinal studies are needed to elucidate the significance of seroconversion prospectively. 6 We did not observe a relationship between rate of seropositivity, number of natalizumab infusions, and duration of natalizumab treatment. This suggests that the increase in PML risk after longer duration of natalizumab therapy may not be due to de novo infection, assuming that the presence of JCV will be reflected by the anti-JCV humoral immune response. However, because the samples were derived from routine anti-natalizumab antibody testing, in our cohort treatment duration was relatively short.
Our finding that immunosuppression before natalizumab treatment was not associated with a higher rate of seropositivity is of special clinical importance because several immunosuppressants preferentially target B-cells and antibody responses. 12, 13 However, our epidemiologic data obtained during open-label treatment may be subject to confounding factors, e.g., recall bias and short treatment duration with natalizumab. However, given that immunosuppressive pretreatment has been associated with a higher risk of developing PML in natalizumab-treated patients with MS, the lack of an increased number of anti-JCV antibody-positive patients after immunosuppressive treatment also suggests that this increased PML risk may not be directly related to de novo JCV infection. This and the proposed negative predictive value for the development of PML in anti-JCV antibody-negative patients with previous immunosuppressive therapy need to be further explored in an independent, prospective study in patients who have been treated with natalizumab for longer periods of time. 9 The correlation of serostatus with other factors remains an open question. Correlation with the presence of JCV DNA in urine has been used to calculate a false-negative rate for the serology assay, previously reported to be 2.5-2.7%. 4, 6 Because of lack of material, we were not able to investigate other JC virus associated biosignatures, e.g., urinary JCV DNA. Therefore, the rate of false-negative findings in our cohort remains open.
Notably, with respect to the use of JCV serology to identify patients at lower or higher risk of developing PML, all sera obtained before and at the diagnosis of PML were anti-JCV antibody-positive. Because all samples were analyzed in a blinded fashion, this study is the first to independently support previous reports that have suggested the use of serostatus for PML risk stratification. 5, 6 However, a more precise quantification of the predictive utility of anti-JCV antibodies determined by the 2-step ELISA will only be discernible in large and prospective studies. Interestingly, the samples obtained before PML diagnosis exhibited considerably higher anti-JC virus antibody reactivity than samples from patients who did not develop PML. This could suggest either a different site of infection or a more robust viral infection in these patients. The possibility that patients with lower anti-JCV antibody levels reflect a distinct type of JCV infection compared with patients who consistently exhibit higher anti-JCV antibody levels should be further investigated.
In summary, this study supports the use of JCV serology as a tool for PML risk stratification. However, the development of additional markers such as JCV antibody levels or surrogate markers of the immunocompetence of patients may provide additional predictive factors that would allow clinicians to further individualize the risk profile for PML development. 14 
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